0ATOS Overview

Stock Split Announcement: Atossa Therapeutics has combined its 15 shares of common stock into one new share following a reverse stock split approved by its Board of Directors, effective February 2, 2026.

FDA Orphan Drug Designation: The FDA granted Orphan Drug Designation to Atossa's drug, Z-endoxifen, for the treatment of Duchenne muscular dystrophy, which is a severe genetic disorder primarily affecting boys.

Stock Performance: Following the stock split, Atossa's shares fell by 32% on the first day of trading, reflecting ongoing concerns among investors about potential dilution and the company's overall performance.

Financial Position: As of the end of September, Atossa reported cash and cash equivalents totaling $51.8 million, despite experiencing a 54% decline in stock value over the past year.